Stock Movers: ASML, Orsted, Galderma (Podcast)

ASML shares rose after the company said surging AI spending has it seeking ways to increase chip-making machine production over the next two years. Orsted fell as much as 4.4% to its lowest since Jan. 21 after the US Justice Department asked a federal court to remand Interior Department approval for its Revolution Wind project. Galderma slipped as much as 1.5% in thin early trading after agreeing to buy Zo Skin Health for $1.5 billion in cash; analysts called the fit good, while Barclays said the multiple was fairly high.

Analysis

The ASML read-through is positive for equipment demand but not automatically for near-term earnings: extra tool output only converts to revenue if specialized components, installation capacity, and customer acceptance keep pace. The market may be capitalizing AI demand before ASML demonstrates incremental shipments or a better delivery cadence. Over 1–3 months, order commentary and capacity milestones matter more than the announcement; over 6–18 months, successful output growth would support leading-edge foundry and memory investment, while potentially easing a key equipment bottleneck.

Ørsted’s risk is not simply a delay to one project. A court challenge to a federal approval can raise perceived permitting and financing risk across US offshore wind, increasing required returns and weakening project economics before any final ruling. Developers with less US exposure may gain relative appeal, but a court remand would be a sector-wide signal; a favorable ruling or narrow procedural outcome could reverse the discount.

For Galderma, strategic fit does not establish value creation: the key is whether physician-channel access and cross-selling generate returns that justify the cash price, without distracting from core execution. Thin-volume trading makes the initial reaction a weak signal. The contrarian angle is that investors may be over-weighting the headline purchase multiple before seeing growth, retention, and integration evidence; equally, strategic rationale alone is not proof of accretion.

Key Decisions for Investors

• ASML: Avoid chasing the immediate strength; consider a staged long on consolidation if subsequent updates confirm higher deliverable tool capacity. Falsify the thesis if output or delivery guidance fails to improve, or customer capex plans soften. Track supplier constraints and shipment/acceptance data.
• Ørsted: Keep exposure underweight pending the court’s next procedural decision; avoid treating the approval challenge as a final project cancellation. Reassess on a ruling or remand, and monitor whether US offshore-wind peers face similar legal challenges. A narrow or favorable outcome would weaken the bearish case.
• Galderma: No immediate trade on the low-volume move. Put the deal on watch pending purchase-price details, funding/cash impact, acquired-business growth and retention, and management’s return or synergy targets. Evidence of weak growth or execution slippage would make the valuation concern more consequential.